Michael A. Blazing

15.6k citations

109 papers · 10.0k indexed · 3 hit papers · h-index 45

Impact in

Cardiology and Cardiovascular Medicine top 0.2%
- Acute Myocardial Infarction Research
- Antiplatelet Therapy and Cardiovascular Diseases
- Cardiac Health and Mental Health
Surgery top 0.2%
- Lipoproteins and Cardiovascular Health

Papers in

Cardiology and Cardiovascular Medicine 55
- Acute Myocardial Infarction Research 17
- Antiplatelet Therapy and Cardiovascular Diseases 16
- Chemotherapy-induced cardiotoxicity and mitigation 10
- Heart Failure Treatment and Management 8
Surgery 65
- Lipoproteins and Cardiovascular Health 55

Co-authors: Robert P. Giugliano Robert M. Califf Jennifer A. White Stephen D. Wiviott Eugene Braunwald Erin A. Bohula Andrew M. Tershakovec Christopher P. Cannon
Journals: Circulation (13 papers)International Journal of Radiation Oncology*Biology*Physics (11 papers)Journal of the American College of Cardiology (11 papers)American Heart Journal (9 papers)The American Journal of Cardiology (7 papers)
Partner nations: United States United Kingdom Canada

In The Last Decade

Michael A. Blazing

107 papers receiving 9.6k citations

Hit Papers

align trajectories log scale

Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes 2015 · 2.9k citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2015 New England Journal of Medicine
2004 JAMA
2001 Archives of Internal Medicine

Peers

Countries citing papers authored by Michael A. Blazing

Since Specialization

Citations

This map shows the geographic impact of Michael A. Blazing's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael A. Blazing with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael A. Blazing more than expected).

Fields of papers citing papers by Michael A. Blazing

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael A. Blazing. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael A. Blazing. The network helps show where Michael A. Blazing may publish in the future.

Co-authors

The 25 scholars most cited alongside Michael A. Blazing, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Michael A. Blazing Line = papers co-authored together Michael A. Blazing links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	In-Hospital Virtual Peer-to-Peer Consultation to Increase Guideline-Directed Medical Therapy for Heart Failure: A Pilot Randomized Trial Circulation Heart Failure ·Vishal N. Rao, Anand Shah, M Ramos-Damián, A. Aliberti, Elde Praga Destirani, Michelle D. Kelsey, Stephen J. Greene, Marat Fudim, Adam D. DeVore, Chetan B. Patel, Michael A. Blazing, Cara O’Brien, Robert J. Mentz	2022	15
2	Cardiovascular Events and Long‐Term Risk of Sudden Death Among Stabilized Patients After Acute Coronary Syndrome: Insights From IMPROVE‐IT Journal of the American Heart Association ·Christopher B. Fordyce, Robert P. Giugliano, Christopher P. Cannon, Matthew T. Roe, Abhinav Sharma, Courtney Page, Jennifer A. White, Yuliya Lokhnygina, Eugene Braunwald, Michael A. Blazing	2022	7
3	Biomarkers and Clinical Cardiovascular Outcomes With Ezetimibe in the IMPROVE-IT Trial Journal of the American College of Cardiology ·Arman Qamar, Robert P. Giugliano, Erin A. Bohula, Jeong‐Gun Park, Petr Jarolı́m, Sabina A. Murphy, Michael A. Blazing, Robert M. Califf, Christopher P. Cannon, Eugene Braunwald, David A. Morrow	2019	26
4	Modeling Survival Distribution as a Function of Time to Treatment Discontinuation: A Dynamic Treatment Regime Approach Biometrics ·Shu Yang, Anastasios A. Tsiatis, Michael A. Blazing	2018	12
5	The nonalcoholic fatty liver disease (NAFLD) fibrosis score, cardiovascular risk stratification and a strategy for secondary prevention with ezetimibe International Journal of Cardiology ·Tracey G. Simon, Kathleen E. Corey, Christopher P. Cannon, Michael A. Blazing, Jeong‐Gun Park, Michelle L. O’Donoghue, Raymond T. Chung, Robert P. Giugliano	2018	51
6	Prevention of Stroke with the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) Circulation ·Erin A. Bohula, Stephen D. Wiviott, Robert P. Giugliano, Michael A. Blazing, Jeong‐Gun Park, Sabina A. Murphy, Jennifer A. White, François Mach, Frans Van de Werf, Anthony J. Dalby, Harvey D. White, Andrew M. Tershakovec, Christopher P. Cannon, Eugene Braunwald	2017	82
7	Abstract 17275: The Natural History of Patients Post-Acute Coronary Syndrome Based on Heart Failure Status - An Analysis of the IMPROVE-IT Trial Circulation ·Andrew P. Ambrosy, Lazo Vázquez Laura, Robert M. Clare, Yuliya Lokhnygina, Andrew M. Tershakovec, Matthew T. Roe, Michael A. Blazing	2017	1
8	Abstract 17307: Biomarkers, Cardiovascular Outcomes and Effect of Ezetimibe After Acute Coronary Syndrome in the IMPROVE-IT Trial Circulation ·Arman Qamar, Robert P. Giugliano, Michael A. Blazing, Tang He-nian, Sabina A. Murphy, Christopher P. Cannon, Eugene Braunwald, David A. Morrow	2017	1
9	Reduction in Total Cardiovascular Events With Ezetimibe/Simvastatin Post-Acute Coronary Syndrome Journal of the American College of Cardiology ·Sabina A. Murphy, Christopher P. Cannon, Michael A. Blazing, Robert P. Giugliano, Jennifer A. White, Yuliya Lokhnygina, Martin Craig, (unknown), Erin A. Bohula, Daniel Isaza, José López‐Sendón, Mikael Dellborg, Uma Kher, Andrew M. Tershakovec, Eugene Braunwald	2016	139
10	Achievement of Dual Low-Density Lipoprotein Cholesterol and High-Sensitivity C-Reactive Protein Targets More Frequent With the Addition of Ezetimibe to Simvastatin and Associated With Better Outcomes in IMPROVE-IT Circulation ·Erin A. Bohula, Robert P. Giugliano, Christopher P. Cannon, Jing Zhou, Sabina A. Murphy, Jennifer A. White, Andrew M. Tershakovec, Michael A. Blazing, Eugene Braunwald	2015	240
11	RISK STRATIFICATION FOR CARDIOVASCULAR EVENTS IN THE IMPROVE-IT TRIAL Journal of the American College of Cardiology ·Erin A. Bohula, Jennifer A. White, Michael A. Blazing, Robert P. Giugliano, (unknown), Andrew M. Tershakovec, Chester C. Platt, Deepak L. Bhatt, Christopher P. Cannon, Robert M. Califf, Eugene Braunwald	2015	3
12	Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: Final baseline characteristics of the IMPROVE-IT study population American Heart Journal ·Michael A. Blazing, Robert P. Giugliano, Christopher P. Cannon, (unknown), Andrew M. Tershakovec, Jennifer A. White, Martin Craig, Chester C. Platt, Eugene Braunwald, Robert M. Califf	2014	80
13	Pain Catastrophizing in Patients with Noncardiac Chest Pain: Relationships With Pain, Anxiety, and Disability Psychosomatic Medicine ·Rebecca A. Shelby, Tamara J. Somers, Francis J. Keefe, Susan G. Silva, Daphne C. McKee, Lilin She, Sandra J. Waters, Indira Varia, N. P Lyamina, Verena Knowles, Michael A. Blazing, James A. Blumenthal, Paige Johnson	2009	24
14	Outcomes of Patients With Acute Coronary Syndrome and Previous Coronary Artery Bypass Grafting (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy [PROVE IT-TIMI 22] and the Aggrastat to Zocor [A to Z] Trials) The American Journal of Cardiology ·Emmanouil S. Brilakis, James A. de Lemos, Christopher P. Cannon, Stephen D. Wiviott, Sabina A. Murphy, David A. Morrow, Marc S. Sabatine, Subhash Banerjee, Michael A. Blazing, Robert M. Califf, Eugene Braunwald	2008	35
15	Serial Measurement of Monocyte Chemoattractant Protein-1 After Acute Coronary Syndromes Journal of the American College of Cardiology ·James A. de Lemos, David A. Morrow, Michael A. Blazing, Petr Jarolı́m, Stephen D. Wiviott, Marc S. Sabatine, Robert M. Califf, Eugene Braunwald	2007	126
16	Evaluation of the National Cholesterol Education Program Adult Treatment Panel III Algorithm for Selecting Candidates for Statin Therapy: Insights from the A to Z Trial The American Journal of Cardiology ·James A. de Lemos, Stephen D. Wiviott, Sabina A. Murphy, Michael A. Blazing, Eldrin F. Lewis, Robert M. Califf, Marc A. Pfeffer, Eugene Braunwald	2006	7
17	Predicting radiotherapy‐induced cardiac perfusion defects Medical Physics ·Shiva K. Das, Alan H. Baydush, S. Zhou, Moyed Miften, Xiaoli Yu, Oana Craciunescu, Mark Oldham, K. Light, Terence Z. Wong, Michael A. Blazing, Salvador Borges‐Neto, Mark W. Dewhirst, Lawrence B. Marks	2004	27
18	The association between depression and chronic kidney disease and mortality among patients hospitalized with congestive heart failure American Journal of Kidney Diseases ·S. Susan Hedayati, Wei Jiang, Christopher M. O’Connor, Maragatha Kuchibhatla, Kavitha Krishnan, Michael S. Cuffe, Michael A. Blazing, Lynda A. Szczech	2004	80
19	Effect on high-density lipoprotein cholesterol of maximum dose simvastatin and atorvastatin in patients with hypercholesterolemia: Results of the Comparative HDL Efficacy and Safety Study (CHESS) American Heart Journal ·Christie M. Ballantyne, Michael A. Blazing, Donald B. Hunninghake, Michael H. Davidson, Žhong Yuan, Paul DeLucca, Karen E. Ramsey, Carolyn M. Hustad, Joanne Palmisano	2003	59
20	The A-to-Z Trial: Methods and rationale for a single trial investigating combined use of low-molecular-weight heparin with the glycoprotein IIb/IIIa inhibitor tirofiban and defining the efficacy of early aggressive simvastatin therapy American Heart Journal ·Michael A. Blazing, James A. de Lemos, Christopher K. Dyke, Robert M. Califf, David W. Bilheimer, Eugene Braunwald	2001	69

About Michael A. Blazing

Michael A. Blazing is a scholar working on Cardiology and Cardiovascular Medicine, Surgery, Internal Medicine, Economics and Econometrics and Cancer Research, having authored 109 papers that have together received 10.0k indexed citations. Recurring topics across this work include Lipoproteins and Cardiovascular Health (55 papers), Pharmaceutical Economics and Policy (20 papers), Health Systems, Economic Evaluations, Quality of Life (19 papers), Cardiac Imaging and Diagnostics (17 papers), Acute Myocardial Infarction Research (17 papers), Antiplatelet Therapy and Cardiovascular Diseases (16 papers), Chemotherapy-induced cardiotoxicity and mitigation (10 papers) and Heart Failure Treatment and Management (8 papers). The work is most often cited by research in Cardiology and Cardiovascular Medicine (4.2k citations), Surgery (5.8k citations), Endocrinology, Diabetes and Metabolism (2.1k citations), Cancer Research (1.3k citations) and Economics and Econometrics (2.1k citations). Michael A. Blazing has collaborated with scholars based in United States, United Kingdom and Canada. Frequent co-authors include Robert P. Giugliano, Robert M. Califf, Jennifer A. White, Stephen D. Wiviott, Eugene Braunwald, Erin A. Bohula, Andrew M. Tershakovec, Eugene Braunwald, Christopher P. Cannon and James A. de Lemos. Their work appears in journals such as Circulation, International Journal of Radiation Oncology*Biology*Physics, Journal of the American College of Cardiology, American Heart Journal and The American Journal of Cardiology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact